Baker Bros. Advisors LP Affimed N.V. Transaction History

Baker Bros. Advisors LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.46 - $0.65 $988,165 - $1.4 Million	-2,148,186 Reduced 32.56%	4,448,644 $2.14 Million
Q2 2022 Aug 15, 2022	BUY	$2.27 - $4.86 $3.28 Million - $7.02 Million	1,443,661 Added 28.02%	6,596,830 $18.3 Million
Q1 2022 May 16, 2022	BUY	$3.69 - $5.65 $9.23 Million - $14.1 Million	2,500,000 Added 94.23%	5,153,169 $22.5 Million
Q4 2021 Feb 14, 2022	BUY	$5.37 - $7.07 $13.4 Million - $17.6 Million	2,488,564 Added 1511.84%	2,653,169 $14.6 Million
Q4 2020 Feb 16, 2021	SELL	$3.16 - $7.03 $79,616 - $177,120	-25,195 Reduced 13.27%	164,605 $958,000
Q3 2020 Nov 16, 2020	SELL	$3.26 - $4.73 $33,252 - $48,246	-10,200 Reduced 5.1%	189,800 $643,000
Q3 2018 Nov 14, 2018	SELL	$1.45 - $6.15 $290,000 - $1.23 Million	-200,000 Reduced 50.0%	200,000 $870,000
Q3 2017 Nov 14, 2017	BUY	$1.95 - $2.25 $780,000 - $900,000	400,000	400,000 $900,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.